EGRIFTA SV® supplies and storage1

EGRIFTA SV® injection supplies

Available in a package of 2 boxes with a 30‑day supply

  • Medication box contains 30 vials of EGRIFTA SV® (2 mg each)
  • Injection box contains a 30‑day supply:
    30 single‑use, 10 mL bottles of reconstitution diluent (Sterile Water for Injection, USP), and disposable:
    • Syringes (60)
    • Reconstitution needles (60)
    • ½” 30‑gauge injection needles (30)
  • EGRIFTA SV® is a once‑daily subcutaneous injection with a small volume of administration
    • Concentrated strength, dosed in a single vial
    • Injection volume of only 0.35 mL
    • Small needle size (½” 30‑gauge needle)
    • Store at room temperature (no refrigeration required)

† Color of reconstitution needles may be different.

Storing EGRIFTA SV® and its injection supplies

Store non‑reconstituted EGRIFTA SV® vials at room temperature (between 20ºC to 25ºC [68°F to 77°F]).

  • EGRIFTA SV® vials should be protected from light and be kept in the original box until the time of use.

Store box of Sterile Water for Injection, USP, syringes, and needles at room temperature (20ºC to 25ºC [68ºF to 77ºF]).

See step‑by‑step instructions for preparing and administering EGRIFTA SV®

Watch Video Now


  1. EGRIFTA SV® (tesamorelin for injection) Prescribing Information. Theratechnologies Inc. October 2019.

IMPORTANT SAFETY INFORMATION (Please see below for full limitations of use and additional important safety information)


EGRIFTA SV® is indicated for the reduction of excess abdominal fat in HIV‑infected adult patients with lipodystrophy.

Limitations of Use:

  • The impact and safety of EGRIFTA SV® on cardiovascular health have not been studied.
  • EGRIFTA SV® is not indicated for weight loss management.
  • It is not known whether taking EGRIFTA SV® helps improve compliance with anti‑retroviral medications.


Do not use EGRIFTA SV® if patient:

  • Has a pituitary gland tumor, has had pituitary gland surgery, has other problems related to their pituitary gland, or has had radiation treatment to their head or a head injury.
  • Has active cancer.
  • Is allergic to tesamorelin or any of the ingredients in EGRIFTA SV®.
  • Is pregnant or planning to become pregnant.

Warnings and Precautions

Drug Interactions

Use in Specific Populations

Adverse Reactions

The most commonly reported adverse reactions include injection site reactions, arthralgia, pain in extremity, myalgia, and peripheral edema.

To report suspected adverse reactions, contact THERA patient support® at 1‑833‑23THERA (1‑833‑238-4372) or FDA at 1‑800‑FDA-1088 or

Please see full Prescribing Information for EGRIFTA SV®.